Daytrana (Methylphenidate) Patent Expiration, LOE Window & CMS Spending
Daytrana (Methylphenidate) by Noven: Off-Patent Genericized (AB Competition), 1 AB generics, $5.0M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Noven |
| FDA Application & Pathway | N021514 (NDA) |
| Exclusivity / Cliff Horizon | Off-Patent Genericized (AB Competition) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 1 |
| 2024 CMS Total Public Spend | $5.0M |
| 2024 Medicare Part D Spend | $144K |
| 2024 Medicaid Spend | $4.8M |
| Reported Wholesale Price Change (CA SB 17) | 4 WAC filings (max 16.8% 2-yr change) |